Cancer Drug Parity Act of 2026
- Sponsor
- Sen. Smith, Tina [D-MN]
- Committees
- Health, Education, Labor, and Pensions Committee (primary)
- Last action
- Jul 15, 2026
Bottom line
The bill aims to equalize out-of-pocket costs for oral and provider-administered chemotherapy drugs, improving financial access to oral cancer treatments for individuals covered by ERISA-governed group health plans.
What it actually does
This bill amends the Employee Retirement Income Security Act of 1974 (ERISA) to mandate that group health plans provide cost-sharing for prescribed oral anticancer drugs on terms no less favorable than for anticancer medications administered by a health care provider (e.g., intravenously or by injection). It includes provisions to prevent plans from increasing overall out-of-pocket costs or reclassifying benefits to circumvent this parity requirement. The bill also commissions a Government Accountability Office (GAO) study to assess its impact.
Proponents argue
Supporters argue that oral anticancer drugs offer significant benefits in terms of convenience and quality of life for cancer patients, allowing them to administer medication at home. They contend that current disparities in cost-sharing create financial barriers, forcing patients to choose less optimal treatments or face undue financial hardship. This bill would equalize access and reduce financial toxicity for cancer patients, ensuring treatment decisions are based on medical necessity rather than cost.
Opponents contend
Opponents, typically health insurers or employers, might argue that mandating parity in cost-sharing could increase overall healthcare premiums or plan costs, potentially impacting affordability for all beneficiaries. They might also express concerns about the potential for increased utilization of expensive oral drugs without adequate cost controls, despite the bill's allowance for prior authorization and other utilization management tools.
The bill is concise and clearly written, making it accessible for a reader to understand its core provisions quickly.
Section 2(a), inserting new Section 727 into ERISA
Mandating Cost-Sharing Parity for Oral Anticancer Drugs
This provision requires group health plans that cover provider-administered anticancer medications to ensure that the cost-sharing (including deductibles, coinsurance, and copayments) for prescribed, patient-administered oral anticancer drugs is no higher than for anticancer medications administered by a healthcare provider (e.g., intravenously or by injection). This mandate applies to FDA-approved drugs that a treating physician finds medically necessary or clinically appropriate for killing, slowing, or preventing cancerous cell growth.
Supporters argue
Supporters argue this provision removes a significant financial barrier for cancer patients, allowing them to choose the most appropriate treatment without cost dictating the decision. It promotes equitable access to modern cancer therapies, many of which are oral, and aligns with the principle that treatment efficacy, not administration method, should determine patient cost.
Critics contend
Some health plans or employers might argue that this mandate could increase overall plan costs, potentially leading to higher premiums for all beneficiaries or reduced coverage in other areas to offset the expense. They might also contend that existing utilization management tools are sufficient to control costs and ensure appropriate use.
Tradeoffs
The bill balances enhanced patient access and affordability for specific cancer treatments against potential increases in overall healthcare costs or premiums for group health plans. It aims to alleviate financial toxicity for cancer patients while acknowledging the cost management concerns of insurers and employers.
Section 727(c) of ERISA, as added by Section 2(a)
Prohibitions on Adverse Changes to Benefits for Compliance
This section explicitly prohibits group health plans from complying with the cost-sharing parity requirement by making changes that would increase out-of-pocket costs for anticancer medications generally, reclassifying benefits in a way that increases such costs, or applying more restrictive limitations on prescribed oral anticancer medications than on intravenously administered or injected ones. This aims to prevent plans from circumventing the intent of the parity mandate by shifting costs elsewhere.
Section 3
Government Accountability Office Study on Impact
This section mandates the Comptroller General of the United States (GAO) to conduct a study within two years of the Act's enactment. The study will assess the impact of the new parity requirement on out-of-pocket costs for oral and patient-administered anticancer medications for individuals in affected group health plans, comparing them to those in plans not subject to the new rule. The GAO must also provide recommendations to Congress on reducing financial barriers to these medications.
This subsection clarifies that the Act does not require the use of orally administered anticancer medications as a replacement for other anticancer medications, does not prohibit a group health plan from requiring prior authorization or imposing other appropriate utilization controls, and does not supersede a State law that provides greater protections with respect to coverage for orally administered anticancer medications.
Section 727(d) of ERISA, as added by Section 2(a)
Why it matters:This is standard legislative practice to clarify the scope of the bill and avoid unintended interpretations or conflicts with existing regulatory frameworks, such as state laws or common plan management tools.
Case for: Supporters argue these clarifications are essential to ensure the bill integrates smoothly into the existing regulatory landscape, preserving necessary cost-management tools for plans while upholding stronger state-level protections where they exist. This prevents unintended consequences and legal challenges.
Case against: Critics might argue that explicitly allowing prior authorization could still create administrative barriers to access, even with cost-sharing parity, potentially undermining the bill's intent to ease patient burden. However, this is a common feature in drug coverage.
Estimated impact: Ensures that health plans retain some flexibility in managing drug utilization and that states can continue to innovate with stronger patient protections, preventing the federal mandate from becoming a ceiling rather than a floor for coverage.